PMID- 20695838
OWN - NLM
STAT- MEDLINE
DCOM- 20101116
LR  - 20211203
IS  - 1875-5704 (Electronic)
IS  - 1567-2018 (Linking)
VI  - 7
IP  - 4
DP  - 2010 Oct
TI  - Phosphodiesterase-5 inhibitor tadalafil acts on endothelial progenitor cells by 
      CXCR4 signalling.
PG  - 274-82
AB  - It has been proposed that endothelial progenitor cells (EPC), originating from 
      the bone marrow contribute to neo-angiogenesis in vivo by forming endothelial 
      cells. Once released in the bloodstream, EPC home at the site of vascular damage 
      where they participate in endothelium regeneration. In this process CXCR4 plays a 
      key role. Recently we demonstrated that a prolonged therapy with 
      phosphodiesterase-5 (PDE5) inhibitors does improve endothelial function and 
      increases circulating EPC, suggesting a role of PDE5 in EPC physiology. Here we 
      tested the expression of PDE5 and CXCR4 on cultured, circulating, and bone marrow 
      resident EPC, and we studied the effect in vivo and in vitro of PDE5 inhibition 
      after administration of a PDE5 inhibitor (tadalafil) on EPC, in term of CXCR4 
      expression. We documented that in vivo and in vitro EPC express both PDE5 and 
      CXCR4, and that tadalafil administration induced a significant increase in EPC 
      number and the relative CXCR4 expression. This effect is inhibited by selective 
      CXCR4 antagonist. We thus demonstrated that PDE5 inhibition acts on CXCR4 
      signalling in EPC and we can suppose an involvement of cGMP second messenger 
      system in both EPC release from the bone marrow and EPC-mediated peripheral 
      re-endothelization.
FAU - Foresta, Carlo
AU  - Foresta C
AD  - Department of Histology, Microbiology and Medical Biotechnologies, Centre for 
      Male Gamete Cryopreservation, University of Padova, Italy. carlo.foresta@unipd.it
FAU - De Toni, Luca
AU  - De Toni L
FAU - Magagna, Sabina
AU  - Magagna S
FAU - Galan, Alessandro
AU  - Galan A
FAU - Garolla, Andrea
AU  - Garolla A
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Drug Deliv
JT  - Current drug delivery
JID - 101208455
RN  - 0 (Benzylamines)
RN  - 0 (Carbolines)
RN  - 0 (Cyclams)
RN  - 0 (Heterocyclic Compounds)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Receptors, CXCR4)
RN  - 742SXX0ICT (Tadalafil)
RN  - EC 3.1.4.35 (Cyclic Nucleotide Phosphodiesterases, Type 5)
RN  - S915P5499N (plerixafor)
SB  - IM
MH  - Adult
MH  - Benzylamines
MH  - Carbolines/antagonists & inhibitors/*pharmacology
MH  - Cells, Cultured
MH  - Cyclams
MH  - Cyclic Nucleotide Phosphodiesterases, Type 5/metabolism
MH  - Endothelial Cells/drug effects/metabolism
MH  - Heterocyclic Compounds/pharmacology
MH  - Humans
MH  - Male
MH  - Phosphodiesterase Inhibitors/*pharmacology
MH  - Receptors, CXCR4/metabolism
MH  - Signal Transduction/*drug effects
MH  - Stem Cells/*drug effects/metabolism
MH  - Tadalafil
EDAT- 2010/08/11 06:00
MHDA- 2010/11/17 06:00
CRDT- 2010/08/11 06:00
PHST- 2010/01/11 00:00 [received]
PHST- 2010/05/26 00:00 [accepted]
PHST- 2010/08/11 06:00 [entrez]
PHST- 2010/08/11 06:00 [pubmed]
PHST- 2010/11/17 06:00 [medline]
AID - BSP/CDD/E-Pub/00029 [pii]
AID - 10.2174/156720110793360595 [doi]
PST - ppublish
SO  - Curr Drug Deliv. 2010 Oct;7(4):274-82. doi: 10.2174/156720110793360595.